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select and prioritize patients for liver transplantation represented
a turning point in organ allocation. Prioritization of transplant
recipients switched from time accrued on the waiting list to the
principle of ‘‘sickest ﬁrst’’.
The MELD score incorporates three simple laboratory parame-
ters (serum creatinine and bilirubin, and INR for prothrombin
time) and stratiﬁes patients according to their disease severity
in an objective and continuous ranking scale. Concordance statis-
tics have demonstrated its high accuracy in stratifying patients
according to their risk of dying in the short-term (three months).
Further validations of MELD as a predictor of survival at various
temporal end-points have been obtained in independent patient
cohorts with a broad spectrum of chronic liver disease. The
MELD-based liver graft allocation policy has led to a reduction
in waitlist new registrations and mortality, shorter waiting times,
and an increase in transplants, without altering overall graft and
patient survival rates after transplantation.
MELD limitations are related either to the inter-laboratory var-
iability of the parameters included in the score, or to the inability
of the formula to predict mortality accurately in speciﬁc settings.
For some conditions, such as hepatocellular carcinoma, widely
accepted MELD corrections have been devised. For others, such
as persistent ascites and hyponatremia, attempts to improve
MELD’s predicting power are currently underway, but await deﬁ-
nite validation.
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MELD; MESO, MELD to serum sodium ratio; PT, prothrombin time.With very few exceptions, orthotopic liver transplantation (OLT)
represents a peculiar scenario where patients with a liver disease
in its terminal stage face a potential cure. Once contraindications
to OLT have been ruled out, however, this apparently straightfor-
ward solution is complicated by a number of factors, namely the
shortage of available organs. In other words, despite being appro-
priate candidates for OLT, some patients waiting for a donor will
die before receiving a suitable organ. In addition, the efﬁcacy of
OLT, i.e., its capacity to prolong patient survival with respect to
the natural history of the disease, is strongly inﬂuenced by the dis-
ease stage in which transplantation is carried out [1]. Too early an
operation could reduce the chances of survival, whereas too late a
transplant would be associated with an unbearable peri-operative
and short-termmortality. Sub-optimal utilization of liver grafts in
a time of scarcity would further exacerbate the harm as the trans-
planted patient would not beneﬁt from having received an organ
that was not offered to another possibly more suitable candidate,
who may well die as a result. Thus, liver allocation policy should
assign grafts to patients most in need. Hence, an ideal tool should
be able to: (a) quantify the patient’s chances of survival in the short
to medium-term for optimum prioritization of patients awaiting
OLT; (b) classify patients according to their disease stage, enabling
doctors to establish whether it is too early, appropriate, or too late
to suggest OLT; (c) predict outcome irrespective of the underlying
liverdisease; (d)be readilymanageable, possiblyat thebedside; (e)
last, but not least for most experts, set aside subjective elements
inﬂuencing the doctors’ judgment, such as features of the trans-
plant center in terms of organization and technical and human
resources, the physician’s individual expertise, which could be
based onpersonal belief rather than evidence-based data, andboth
personal andenvironmental emotional pressure. Theanswer to the
question: ‘‘Do we possess such an ideal tool?’’ is, unfortunately,
‘‘No’’. However, themodel for end-stage liver disease (MELD) score
has brought us close to this goal. As with all outstanding achieve-
ments, the MELD score still has to be challenged, but it will not
be easy to surpass its efﬁcacy and ﬂexibility.The impact of MELD on the liver allocation policy: the score
demonstrates it strengths
Once its pioneering phase was over and OLT became the standard
of care for patients with end-stage liver disease, it became clear11 vol. 54 j 1297–1306
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Fig. 1. Unadjusted death rates per 1000 patient-years of OLT candidates on
the waiting list in the pre-MELD era (light blue) and in the post-MELD era
(dark blue) in the United States (data from Ref. [16]). (For interpretation of the
references to color in this ﬁgure legend, the reader is referred to the web version
of this article.)
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that an allocation policy based on a ﬁrst-come, ﬁrst-served prin-
ciple, with the time accrued on the waiting list as a major prior-
itizing factor, was largely inadequate. Many patients most in
need of transplantation because of disease severity, but only just
included in the waiting list lost their chance of receiving an organ
because less severely ill patients had been waiting for a long time
[2]. This inadequacy was exacerbated by a lack of a standardized
practice among transplant centers. The ﬁrst attempt to overcome
this weakness was made by the United Network for Organ Shar-
ing (UNOS) in the United States by implementing a categorical
system that stratiﬁed patients according to disease severity.
However, severity was indirectly assessed according to the inten-
sity of care the patient needed, decreasing from the intensive care
unit (status 2) to home management (status 4) with emergency
cases, deemed to have a chance of survival shorter than 24 h,
assigned to status 1 deserving the highest priority. The vagueness
of the boundaries between these categories, which could be
strongly inﬂuenced by a center’s organization and physicians’
attitudes, is self-evident. In addition, waiting time was again a
discriminant factor within each category, and this was particu-
larly signiﬁcant in the broadest categories, such as statuses 3
and 4.
To enhance the role of disease severity in the organ allocation
policy, UNOS adopted a new classiﬁcation by merging the pres-
ence of certain clinical features with the Child-Turcotte-Pugh
(CTP) score [3,4], which is based on two discrete clinical variables
(ascites, encephalopathy) and three continuous laboratory vari-
ables (serum albumin and bilirubin, and prothrombin time) to
which a score from 1 to 3 is given according to the magnitude
of their derangement. Speciﬁc cut-offs for serum bilirubin are
employed for cholestatic diseases. First conceived to assess the
outcome of cirrhotic patients undergoing porto-caval shunt sur-
gery [5] or esophageal transection for bleeding varices [6], this
score system had become the most popular tool for estimating
the severity of chronic liver disease and patient prognosis. How-
ever, this classiﬁcation had not been validated as a tool to predict
mortality on the waiting list for OLT, a setting where shortcom-
ings blunted its full efﬁcacy. The CTP score components had been
selected empirically, as had the cut-off values for each variable. It
was also assumed that each variable possesses the same weight,
which has not been demonstrated, and that variables were inde-
pendent of each other, which may not be the case for serum albu-
min concentration and prothrombin time. In addition, clinical
variables have to be judged subjectively, and the assignment to
the three classes results in categories that certainly differ in
terms of prognosis, but are broad enough to accommodate
patients with substantially different disease severities. Such a
ceiling effect is particularly important for patients belonging to
class C. Nor was the CTP-based UNOS system able to overcome
this problem, as it included only four categories, again resulting
in many patients being grouped into each category. Thus, patients
who most needed OLT in the short-term, ended up competing
with those that could wait longer because of a less severe disease
on the basis, once again, of the time spent on the waiting list.
Nonetheless, an initial reduction in waitlist mortality ensued
(Fig. 1).
In 2000, Malinchoc and coworkers from the Mayo Clinic in
Rochester [7] devised a mathematical model to predict the out-
come of elective placement of transjugular porto-systemic shunt
in patients with cirrhosis and portal hypertension, named the
Mayo End-stage Liver Disease (MELD) score. This model proved1298 Journal of Hepatology 2011to predict the probability of death within three months after
the procedure. Subsequently, the model name was changed to
Model for End-stage Liver Disease and it was successfully vali-
dated in patient cohorts with different liver disease severity,
and different geographical and temporal origin [8]. The original
model incorporated three simple laboratory parameters, serum
creatinine, serum bilirubin, and international normalized ratio
(INR) for prothrombin time, along with the etiology of cirrhosis
as the fourth variable. Further studies showed that the accuracy
of MELD was preserved after eliminating the variable related to
the etiology of cirrhosis [8] that could allow some degree of sub-
jective freedom in its deﬁnition, thus leaving a score based only
on objective laboratory parameters. Concordance (‘‘c’’) statistics
demonstrated the high accuracy of MELD in stratifying patients
according to their risk of dying in the short-term (three months),
as many studies reported c-statistics close to or even higher than
0.8, a value reﬂecting a predictive power of high clinical signiﬁ-
cance, and usually superior to that of the CTP score [8–10]. Fur-
ther validations of MELD as a predictor of survival at various
temporal end-points were obtained in independent cohorts of
patients with a broad spectrum of chronic liver disease [11–13].
MELD has several features of an ideal prognostic model to pre-
dict the probability of survival: it only incorporates simple and
objective variables readily determined in all laboratories, and
each variable is weighted according to its inﬂuence on prognosis.
The score is independent from the etiology of liver disease, and,
hence, does not need adjusting in this respect. It also possesses
a high predictive power and provides a continuous ranking of dis-
ease severity, thereby overcoming the ceiling effect of the CTP
score. Thus, the time came for a sickest-ﬁrst policy to be reliably
fulﬁlled, and the MELD score became the means to allocate liver
grafts in the United States of America from February 2002. The
organ allocation system had at last got rid of the inﬂuence of
accrual time on the waiting list, and patients were unchained
from rigid categorizations that had often under- or overestimated
their actual priority. In the OLT setting MELD is calculated differ-
ently from the original formula that directly incorporated the
measured values of the variables, by ﬁxing their lower limit at
1 to avoid negative scores; in addition, serum creatinine value
is capped at 4 mg/dl.vol. 54 j 1297–1306
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Fig. 2. Median waiting time to OLT after the implementation of MELD in 2002
in the United States (data from Ref. [16]).
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The impact of the MELD-based liver graft allocation policy on
the OLT system has been impressive: new registrations on the
waiting list suddenly dropped, interrupting a growing trend that
had accompanied OLT for several years. The removal rate for
death or disease progression (‘‘too sick’’) also steadily declined
[9,10,14–16] (Fig. 1). A slight increase in organ availability could
have contributed to the reduction in waiting list mortality, but it
is generally agreed that this has mostly been due to MELD imple-
mentation [17]. Further advantages associated with the change in
allocation policy were a decrease in the median waiting time to
OLT (Fig. 2), an increase in the number of deceased donor trans-
plants and the steadiness in the overall patient and graft survival
rate after transplantation, with the exception of candidates with
extreme MELD values exceeding 30 [14,16,18–20]. These favor-
able results led many transplant centers worldwide to adopt
the MELD-based way of ranking and prioritizing candidates for
OLT. Moreover, MELD has progressively been employed as a prog-
nostic tool for patients with chronic liver disease outside the
transplant setting for conditions, such as variceal bleeding, bacte-
rial infections, fulminant liver failure, alcoholic hepatitis, and sur-
gery other than OLT. A detailed discussion of these applications of
MELD is beyond the limits of this review; interested readers can
refer to many recent ﬁne reviews [10,21–23].Conditions not properly accounted for by MELD: the score
shows its weaknesses
The MELD score succeeds in deﬁning the three-month death risk
of patients with non-malignant end-stage liver disease and it has
proved a reliable tool for prioritizing these patients in the OLT
waiting list. There are conditions, however, that are not properly
accounted for by the MELD score, either because they are not suf-
ﬁciently ‘‘perceived’’ and weighted by the variables included in
the score, or because their short-term risk in the waitlist is pro-
gression beyond the limit of transplant suitability, rather than
death (Table 1).
Conditions implying speciﬁc end-points for prioritization
To overcome this potential shortcoming, modiﬁcations consisting
in adding points to the calculated MELD score have been pro-
posed, some of which are widely employed the world over. How-
ever, these adjustments were created arbitrarily, often without
scientiﬁc evidence, with the purpose of avoiding an advantageous
or disadvantageous prioritization vis-à-vis cirrhotic patients
without these conditions for whom the MELD score had been
validated.
Hepatocellular carcinoma (HCC)
A typical example of the conditions described above is HCC,
which apparently involves a minority of patients in the waiting
list. Indeed, reports from European [24] and US [16] transplant
registries indicate a prevalence of 8% and 2%, respectively. These
low ﬁgures, however, reﬂect the fact that only cases with HCC as
a primary diagnosis are clearly identiﬁed, whereas data elabora-
tion discloses that about 10–20% of patients in the waitlist have
HCC.
HCC often arises in patients with fairly well-preserved liver
function and low MELD score, so that their risk is more oftenJournal of Hepatology 2011related to tumor progression beyond the stage ensuring a favor-
able outcome with transplantation, than death on the waiting list
because of terminal liver failure due to the underlying cirrhosis.
Of course, this concept is valid irrespective of the transplant cri-
teria for HCC [25,26] adopted by individual centers.
At ﬁrst, based on the evaluation of their three-month death
probability, patients with stage T1 HCC (single tumor 61.9 cm)
received a MELD score of 24, while patients with stage T2 (single
tumor 2–5 cm, or two to three nodules all <3 cm) received a score
of 29 [27]. This system led to a sudden increase in the transplant
rate of patients with HCC. More than 87% of these patients under-
went OLT within three months of listing [28], raising concerns
about an excessive priority given to HCC candidates with respect
to patients without HCC [29]. Following studies reporting a much
lower progression risk [27,29,30], the exception MELD score for
HCC candidates was adjusted downward: at ﬁrst, patients with
T1 lesions were given a score of 20, but additional points were
subsequently eliminated [31] once the inaccuracy of imaging
techniques for small lesions, not conﬁrmed in the explanted liver,
had been ascertained [32]. Prioritization was also reduced for
candidates with T2 lesions: at ﬁrst they were given a score of
24, reduced more recently to 22. However, patients with HCC
in stage T2 have their score upgraded by three points for every
three months on the waiting list as long as tumor burden remains
within the established criteria for OLT [33].
As it emerges from these subsequent adjustments, adaptation
of the MELD score to ‘‘special’’ conditions consists of an ongoing
revision, where further reﬁnements emerge from an analysis of
clinical outcomes. As examples, the current MELD adjustment
for prioritizing HCC patients at our center consists in adding three
points to the real MELD for T1 lesions and six points for T2
lesions, then adjusting the score by 0.5 or one point, respectively,
for each month spent on the waiting list [34]. The potential
advantage of this approach is to maintain the prediction of the
waitlist mortality risk due to the worsening of liver failure (the
real MELD score), and give an adequate weight to the additional
risk of drop-out related to the tumor. An alternative method,
whose main advantage is to compute the risk of drop-out on a
continuous basis as for candidates without HCC, was pursued
by devising a new equation including maximum tumor size and
alfa-fetoprotein level besides the MELD score [35].
Other conditions
There are several other conditions in which application of the ori-
ginal MELD would not allow an adequate patient prioritization
because of the risk of dropping out of the waitlist as disease pro-vol. 54 j 1297–1306 1299
Table 1. Conditions not properly accounted by MELD score.
Impact on outcome in the waitlist Potential solutionsConditions implying specific 
end-points for prioritization
Hepatocellular carcinoma Progression beyond the Milano criteria Added points to MELD to allow OLT before progression
Hepatopulmonary syndrome Progression to severe hypoxemia Added points to MELD to allow OLT 
a-v shunt fraction ≥20% 
Portopulmonary hypertension  Progression to severe pulmonary  Added points to MELD to allow OLT before mean 
pulmonary artery pressure >35 mmHg despite 
ongoing treatment with vasodilators
Familial amyloidosis Progression to polyneuropathy, 
cardiac involvement, 
poor nutritional status
Added points to MELD to allow OLT before critical 
progression
Combined heart / liver transplantation
Conditions potentially 
underweighted by MELD score
Complications of portal hypertension* Increased risk of waitlist mortality Integration of new variables into the MELD model
Hyponatremia Increased risk of waitlist mortality Integration of serum Na into the MELD model 
(see: MELD-Na)
(see: MELD-AS)
Malnutrition Increased risk of waitlist mortality Integration of variables related to nutritional status into 
the MELD model; not yet proposed 
Viral (hepatitis B and C) cirrhosis Potentially higher mortality risk desoporpsnoitulosoN.dedeenseidutsrehtruF
Female gender Higher mortality risk than males Serum creatinine corrected by gender
(see: MELD modified by gender)
Patients listed 
with low MELD score (<21)
tsiltiawfoytilibatciderpdecudeR
mortality 
New scores with extended (≥1 yr) prediction ability
hypertension
than alcoholic cirrhosis
before PaO2 <50 mmHg on room air and/or 
OLT, orthotopic liver transplantation; a-v: artero-venous; MELD-AS, MELD-ascites-Na score.
⁄Includes: ascites, hepatic encephalopathy, hepatorenal syndrome, esophageal variceal bleeding; spontaneous bacterial peritonitis.
Frontiers in Liver Transplantationgression reaches speciﬁc stages contraindicating OLT (Table 1).
Just a few examples are patients with hepatopulmonary syn-
drome showing an unmodiﬁable PaO2 <50 mm Hg [36], patients
with portopulmonary hypertension exceeding 35 mm Hg even
after treatment [37], and patients with familial amyloidosis hav-
ing developed signiﬁcant cardiac involvement or autonomic neu-
ropathy [38]. The answer to the needs imposed by these
conditions remains unstandardized among transplant centers
worldwide [39–41]. However, the number of patients with these
conditions currently in the waitlists is below 3% [16,24].
Thus, MELD can also serve to prioritize patients listed for OLT
when their transplant needs differ from those of the original
MELD criteria, even though adjustments are necessary. This adap-
tation process has to be seen as a progressive reﬁnement of the
adjusted MELD, and data suggesting that the probability of
removal from the waitlist are higher for standard MELD cases
than for exceptional cases [42] show that further work has to
be done in this ﬁeld. Nevertheless, this does not invalidate the
usefulness and versatility of the MELD score.
Conditions potentially underweighted by the MELD score
Advanced cirrhosis is jeopardized by complications, most of
which directly or indirectly related to portal hypertension, such1300 Journal of Hepatology 2011as hepatic encephalopathy, esophageal variceal bleeding, refrac-
tory ascites, hepatorenal syndrome, severe malnutrition, and bac-
terial infections. All these complications imply a poor prognosis
and a high risk of death [23]. However, the variables included
in the MELD formula are not always inﬂuenced by these condi-
tions, so that the disease severity of patients awaiting OLT can
be underweighted.
Complications of portal hypertension
Huo et al. [43] investigated the association with MELD of compli-
cations related to portal hypertension (hepatic encephalopathy,
hepatorenal syndrome, ascites, esophageal variceal bleeding,
and spontaneous bacterial peritonitis), and their impact on sur-
vival in a large cohort of patients with non-cholestatic cirrhosis.
As expected, they showed that these complications are time-
dependent prognostic predictors of mortality, and found that
the mortality risk increased for each additional episode of com-
plications. However, patients developing complications did not
necessarily have a higher MELD score and could be overlooked
during the process of organ allocation. These results have been
conﬁrmed to some extent, as MELD score did not correlate with
the severity of ascites and hepatic encephalopathy in a further
study [44]. Thus, it appears that such high-risk patients need tovol. 54 j 1297–1306
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be identiﬁed better and earlier, and this may help to decrease
waitlist mortality. An answer to this need, however, is currently
lacking.
Hyponatremia
Another powerful prognostic factor not incorporated in the MELD
formula is hyponatremia. Hyponatremia is linked to impaired
renal function induced by the hemodynamic abnormalities that
develop in advanced cirrhosis. It is often associated with refrac-
tory ascites and hepatorenal syndrome [45,46] and implies an
increased incidence of complications and a high mortality rate
[47,48]. The prognostic importance of hyponatremia has been lar-
gely conﬁrmed in the OLT setting. Indeed, three retrospective sin-
gle-center studies [49–51] and a prospective multi-center study
[52] agreed that hyponatremia is a strong independent mortality
predictor. Interestingly, the risk of waitlist mortality appears to
increase by 12% for each unit of decrease in serum sodium con-
centration for values between 120 and 135 mmol/L [53]. These
ﬁndings have led to several attempts to integrate serum sodium
into the MELD formula. The advantages and potential pitfalls of
these modiﬁed scores are reported below.
Malnutrition
Cirrhotic patients are often malnourished due to poor dietary
intake, intestinal protein loss, low protein synthesis, abnormali-
ties in substrate utilization, and hypermetabolism [54]. Malnutri-
tion is frequently under diagnosed, also because a gold standard
to deﬁne nutritional status in cirrhotic patients is lacking [55,56].
Malnutrition worsens liver function in cirrhotic patients [57]
resulting in higher morbidity and mortality [58,59]. The adverse
prognostic signiﬁcance of malnutrition has long been recognized,
and this variable was included in calculating the original Child-
Turcotte score [5]. Indeed, malnutrition has proved to be an inde-
pendent predictor of mortality at six, 12 and 24 months in
patients with cirrhosis [58], and the in-hospital mortality of mal-
nourished patients is almost twofold higher than that of patients
without malnutrition [56]. Interestingly, malnutrition enhances
the risk of complications and mortality both in patients with
advanced cirrhosis [56] and in those belonging to CTP class A
[60]. To date, no attempts have been made to assess whether
parameters related to malnutrition actually improve the MELD
predictive power.
Acute complications of cirrhosis and the use of artiﬁcial liver support
systems
Patients belonging to the cohorts where MELD was originally cre-
ated and validated [7,8] were in stable conditions, and potentially
reversible complications, such as bacterial infections, acute renal
failure, and ongoing gastrointestinal hemorrhage had been
resolved at the time of data collection. Thus, caution has to be
exerted in calculating the MELD score during an acute, but poten-
tially reversible, deterioration of patient conditions, as it may not
accurately predict short-term mortality in such circumstances.
Interestingly, the occurrence of hepatorenal syndrome type 1
effaces the predictive ability of MELD [61].
The picture can be complicated even further by artiﬁcial liver
support systems. Growing attention has focused on these devices
to treat speciﬁc conditions, such as severe jaundice or pruritus, orJournal of Hepatology 2011bridge patients with acute-on-chronic liver failure to OLT [62,63].
However, while it is undisputed that these devices can efﬁciently,
but often transiently, lower at least one of the triad parameters
included in the MELD score, i.e. bilirubin, it has yet to be demon-
strated whether they also enhance short-term survival [64]. Thus,
a consensus must be reached on when to calculate MELD in
patients awaiting OLT and receiving artiﬁcial liver support.
Other potential pitfalls
As already reported, the removal of cirrhosis etiology from the
variables employed to compute the MELD score did not appear
to affect its predictive accuracy [8]. Nevertheless, Angermayr
et al. found that the prediction of survival beyond three months
in patients with viral cirrhosis and MELD P16 is not precisely
assessed [65]. Moreover, Lucey et al. demonstrated that MELD
is a stronger predictor of waitlist mortality in non-alcoholic than
alcoholic patients [66]. Thus, the role of cirrhosis etiology in
assessing the mortality risk in cirrhotic patients cannot be seen
as a deﬁnitely resolved issue.
Gender has recently emerged as a factor that can signiﬁcantly
inﬂuence access to OLT, as shown by a large study in the UNOS
database reporting that, in the MELD era, women experienced
around 30% increased probability of drop-out from the waiting
list because of death or becoming too sick for transplant com-
pared to men [67]. Although liver allocation to women could be
inﬂuenced by factors such as graft size, such a disparity also
depends on lower serum creatinine values. Indeed, females exhi-
bit a worse renal function, as measured by GFR, with respect to
males with similar MELD scores [68], thus being disadvantaged
in calculation of the score [68,69].
Lastly, although MELD undoubtedly succeeds in predicting the
short-term mortality risk in end-stage liver disease, such a risk
may not be adequately assessed in patients with a prolonged stay
on the waiting list and/or with a less severe disease. The superiority
of MELD’s predictive power with respect to CTP has been repeat-
edly reported. However, several studies have shown that CTP has
the same ability to predict mortality or removal from the waiting
list as MELD [70], or is even superior [71]. Such variant results are
likely related to the inclusion of patients with a less severe liver
disease [70] and/or an observation period extending up to a year
[71]. Thus, the development of new scoring systems ﬁtting these
conditions may be advisable.Intrinsic weaknesses of the MELD score: the shortcomings of
its components
The three variables included in the MELD formula were selected
by a robust statistical approach [8] but each shows some
limitations.
(1) Serum creatinine. First, serum creatinine is inﬂuenced by
muscle mass, protein dietary intake, age, sex, and ethnicity
[72]. Because of muscle wasting, patients with advanced cirrhosis
present lower serum creatinine than the general population [72–
74]. Thus, a normal serum creatinine does not exclude a signiﬁ-
cant impairment in renal function [75]. Second, serum creatinine
can ﬂuctuate considerably in the short-term in patients with
massive or refractory ascites undergoing diuretic treatment, large
volume paracentesis, and plasma volume expansion leading to
MELD ﬂuctuations that likely do not reﬂect a change in the actualvol. 54 j 1297–1306 1301
Table 2. MELD-derived models.
MELD-
derived
Equations Strengths Limitations
[Ref]
[74]
[89]
[90]
[39]
[94]
[71]
[55]
[96, 97]
For all the scores including serum Na: rapid 
spontaneous and iatrogenic Na variability 
MELD-Na 95.1+DLEM  (135  Na) More accurate in 6-
month mortality prediction
Derived from a retrospective study, not validated, 
limited number of deaths  during the follow-up period 
DLEMaN-DLEM  Na 
 [0.025  MELD  (140  Na)] + 140 
More accurate in 3-
month mortality prediction
Validated in a large
Derived from a retrospective study, based on a non-
specific database 
(waiting-list registry) 
iMELD  MELD + (age  0.3)  (0.7  Na) + 100 More accurate 3-, 6-,
and 12-month mortality 
Derived from a retrospective study, validation group 
including HCC 
Advantages older recipients, who show  lower post-
OLT patient and graft survival 
593.5([DLEKU  ln(INR)) + (1.485 
ln(creatinine)) + (3.13 x ln(bilirubin)) 
565.18(  ln(Na))] + 435 
rofatadfokcal,ydutsevitcepsorteramorfdevireDetarapesanidetadilaV
comparison with MELD 
MESO  MELD / Na Higher predictive value anodetsetton,ydutsevitcepsorteramorfdevireD
waiting list population 
hgihhtiwstneitapseifitnedI)seticsatnetsisrepfi(64.4+DLEMSA-DLEM
mortality risk despite low 
Derived from a retrospective study, not superior to 
standard MELD with scores 21 
Updated 662.1  ln(1 + creatinine) 
+ 0.939 x ln(1+bilirubin) +
1.658  ln(1 + INR) 
dnahtnom-3etaruccaeroM
and overall predictor of 
Derived from a large sample  
Derived from a retrospective study, based on a non-
specific database 
(waiting-list registry) 
DLEMDLEM 2  MELD1 Dynamic evaluation lavretniemit,ydutsevitcepsorteramorfdevireD
between assessment not defined 
prospective cohort 
than MELD
of disease progression
MELD 
population
prediction 
MELD score
mortality
size
+ 4.53 (if Na <135)
models
Frontiers in Liver Transplantationmortality risk [72,75]. Lastly, a signiﬁcant bias in calculation of
the MELD score can derive from the use of different assays for
creatinine in different laboratories [76]. This variability is exacer-
bated by the analytical interference of bilirubin, a chromogen,
when the colorimetric Jaffé method is employed. When serum
bilirubin exceeds 10 mg/dl, falsely low serum creatinine readings
can ensue, an effect that is enhanced in parallel with the increase
in bilirubin [77]. This would underestimate the MELD score in
deeply jaundiced and usually the sickest patients, who have the
greatest priority for OLT. In such cases, enzymatic methods are
far more accurate and their use is highly advisable [78].
The equations based on serum creatinine such as the Cockroft-
Gault formula and the Modiﬁcation of Diet in Renal Disease,
which is considered the gold standard measure of renal function
by nephrologists [79], overestimate the actual glomerular ﬁltra-
tion rate (GFR) in cirrhotic patients [72,75]. Theoretically, creati-
nine clearance should be more reliable, but it also overestimates
GFR in cirrhosis because of increased tubular secretion of creati-
nine, especially in patients with low GFR [80]. This limitation
could be overcome by direct GFR measurement, but unfortu-
nately this is inappropriate for routine use because of costs and
complexity [75].1302 Journal of Hepatology 2011As reported above, by applying MELD to the organ allocation
system, UNOS introduced changes in how the score was calcu-
lated, setting lower, as for the other variables, and upper limits
for creatinine. Both these changes have been criticized. Bounding
lower serum creatinine levels to 1 mg/dl to avoid negative values
after logarithmic transformation implies that mortality is con-
stant for values below 1 mg/dl. Such an assumption, however,
is doubtful because all changes in serum creatinine levels reﬂect
changes in GFR [81]. Thus, it has been proposed to eliminate the
lower limit for creatinine, a change that would lead to better
results with respect to the standard MELD score [81]. The 4 mg/
dl capping, introduced to avoid excessively high scores in candi-
dates with intrinsic renal disease, has also been recently chal-
lenged. Indeed, no outcome data justify this choice, and
capping creatinine in patients who were not uremic or on dialysis
may yield a MELD score that underestimates disease severity in
the sickest patients [82].
(2) Serum bilirubin. Like creatinine, serum bilirubin determina-
tion can vary among different laboratories [83]. Apart from this
limitation, which can hardly be resolved, it should not be disre-
garded that patients with cholestatic liver disease showed a
lower waitlist mortality than patients with non-cholestaticvol. 54 j 1297–1306
0 02 04 06 08 001
100 - Specificity
100
80
60
40
20
0
100
80
60
40
20
Se
ns
iti
vi
ty
Se
ns
iti
vi
ty
iMELD AUC 0.806
MELD-Na AUC 0.798
MELD AUC 0.759
iMELD AUC 0.792
MELD-Na AUC 0.765
MELD AUC 0.724
3 months
6 months
A
B
JOURNAL OF HEPATOLOGY
disease [14]. Thus, the original assumption that disease etiology
could be avoided without altering MELD score reliability [8]
may not be valid in all settings. Finally, it has yet to be investi-
gated whether direct, rather than total bilirubin, more accurately
predicts mortality in end-stage liver disease as it is less inﬂu-
enced by extrahepatic or benign causes of jaundice.
(3) INR. Prothrombin time (PT) is a long-recognized indicator
of liver function and has been widely employed to assess the
prognosis of patients with liver disease [23]. The recent demon-
stration that PT prolongation in cirrhosis does not reﬂect an in-
creased risk of bleeding [84], as the synthesis of both
coagulative and anti-coagulative factors is depressed, does not
detract from its potential as a prognostic factor. However, it
should not be forgotten that PT INR was originally developed to
predict bleeding and thrombotic risk under oral anticoagulants
in non-cirrhotic patients [85]. Although attempts have recently
been made to modify INR to adapt it to the setting of cirrhosis
[86,87], the deﬁnite validation of these new indices is still pend-
ing and this continues to represent a limitation.
Another weakness is the huge inter-laboratory variability in
PT, which has not been removed by the introduction of INR
[85]. Inter-laboratory INR variability in patients with liver disease
leads to a median MELD score difference between the highest and
lowest scoring laboratories of three to ﬁve points, with individual
differences reaching up to eleven or twelve points [88–90]. The
impact of such variability on the organ allocation system is
self-evident.0 02 04 06 08 001
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ig. 3. ROC curves for best predictors of dropout from the waiting list with
spect to standard MELD at 3 and 6 months (data from Ref. [101]). Despite
oth iMELD and MELD-Na showed a higher AUC in respect to standard MELD at
months, the comparison between AUCs showed that only MELD-Na had a
gniﬁcantly better prognostic power than the standard MELD, because of the
ery small standard error (0.018) in the difference between the areas (0.039).Attempting to overcome MELD limitations: the ‘‘new’’ MELD
scores (Table 2)
Among the prognostic factors that could be incorporated into the
MELD formula in an attempt to improve its reliability, hyponatre-
mia has received the broadest attention. Biggins et al. [52] pro-
posed a MELD-based score, called MELD-Na, resulting from the
integration of serum sodium into MELD, which more accurately
predicted the six-month survival of cirrhotic patients awaiting
OLT. More recently, a study based on a larger sample [91] modi-
ﬁed the previous MELD-Na formula by ﬁxing the lower and upper
limits of the serum sodium concentration to 125 and 140 mmol/
L, respectively, and suggested that the new score offers a better
short-term mortality prediction. It also emerged that the inﬂu-
ence of hyponatremia was mainly evident in patients with a
MELD score below 30. However, the applicability of Na-based
MELD scoring systems in organ allocation also has some limita-
tions due to inter-laboratory differences and the potential vari-
ability of serum sodium concentration after simple therapeutic
maneuvers, such as diuretic administration, plasma volume
expansion, or hypotonic ﬂuid infusion.
As age is strongly associated with a higher mortality in cirrho-
sis [23], an attempt has been made to integrate MELD variables
with serum sodium and age [92]. The resulting score, called inte-
grated MELD (iMELD), seems to predict three-, six- and 12-month
survival more precisely than standard MELD. However, age inclu-
sion in this setting could raise ethical issues, as OLT in older
recipients is associated with lower patient and graft survivals
[93,94].
Other scores that add natremia to the original MELD formula
include the United Kingdom model for End-stage Liver Disease
(UKELD) and the MELD to serum sodium ratio (MESO). The UKELDJournal of Hepatology 2011F
re
b
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si
vwas developed by analysis of 1103 patients and validated in a
separate prospective cohort study [40,95]. TheMESO is calculated
by dividing the MELD score by the serum sodium concentration,
and proved to possess a higher predictive value than standard
MELD [96]. This score, however, was tested in non-waitlisted cir-
rhotic patients.
In general, scores resulting from the integration between
serum sodium and MELD seem to enhance MELD’s predictive
power in patients with low MELD scores [50,52]. In this subset,
point addition for the presence of persistent ascites (MELD-AS) fur-
ther improved the prediction of six-month mortality when stan-
dard MELD score was 21 or lower [49]. The importance of ascites
has been further conﬁrmed as its presence in patients with
MELD-Na below 21 identiﬁed those with a high one-year mortal-
ity risk independently from their MELD or MELD-Na scores [97].
Moreover, the addition of ascites to the MELD-Na formula
improved its one-year mortality prediction ability [97].
The demonstration that patients with high serum creatinine
have a lower waitlist mortality than those with low values,
whereas patients with the highest bilirubin have the highest
mortality, has led to the proposal of ‘‘updated MELD’’, assigningvol. 54 j 1297–1306 1303
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a lower weight to creatinine and INR, and a higher weight to bil-
irubin [81]. The resulting score better predicted overall and 90-
day mortality on the waiting list than standard MELD.
The MELD score is not a time-dependent model, since it is
computed by a single measurement of laboratory parameters.
In an attempt to weight the time-related changes, the Delta MELD
(DMELD), deﬁned as the difference between the MELD score cal-
culated at two time points, has been proposed [98,99]. Once
again, the new score was able to predict the mortality risk of
OLT candidates more accurately than standard MELD score alone.
Nevertheless, its usefulness in predicting survival on the waiting
list is still debated [100].
We recently compared the performance of most MELD-based
scores in waitlisted patients [101]. Our data suggest that the most
accurate scores to predict the drop-out rate from the waiting list
are MELD-Na and iMELD. MELD-Na is the best drop-out predictor
at three months, while both scores performed well at six months
(Fig. 3).
Lastly, there are some clinical conditions that cannot be ade-
quately evaluated by the standard MELD score. Patients with
Budd-Chiari syndrome, or other thrombophilic syndromes, are
commonly treated with oral anticoagulants [102] which improp-
erly modify INR and, therefore, the MELD score. To overcome
this problem, Heuman et al. [103] developed a score omitting
INR.Conclusions
The adoption of MELD to select and prioritize patients, and regu-
late organ allocation in the setting of OLT has brought substantial
advantages and constituted a signiﬁcant clinical turning point.
The impact of MELD on the OLT system has been so strong that
the period following implementation of the new score is often
referred to as the ‘‘MELD era’’. The predictive strength of the
MELD score for short-term mortality is such that it will be
employed in many more settings other than the OLT waitlist
for which it was conceived and validated. Like all human achieve-
ments, MELD is not perfect and has its weaknesses. Many
attempts are underway to improve the applicability and reliabil-
ity of the formula in speciﬁc conditions. However, virtually all
these proposals continue to be based on the original MELD score,
conﬁrming its peculiar versatility, a feature that may well prove
its greatest strength.1304 Journal of Hepatology 2011Conﬂict of interest
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